JANX - Janux Pharma P/S multiplikatori

Janux Corp (JANX) tovar belgisi

Janux Therapeutics (JANX) klinikalarga mo‘ljallangan maqsadli saraton terapiyalarini ishlab chiqadi, bu esa kompaniyaning P/S koeffitsiyentida aks etgan. 29.80 qiymati joriy ko‘rsatkichni ifodalaydi. Aksiyalar opsionlari bilan rag‘batlantirilgan yetakchi olimlar ishlab chiqish jarayonini boshqarmoqdalar. Makroiqtisodiy tebranishlardan himoyalanganligi va innovatsiyalarga bo‘lgan barqaror talab tufayli, ushbu biznes retsessiya davrlarida defensiv aktiv vazifasini o‘taydi.

JANX (Janux Pharma) Narxning daromadga nisbati tarixi 04.07.2022dan 15.11.2026gacha

Janux Pharma (JANX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning umumiy tahlili:Janux Therapeutics, Inc., JANX
Janux Therapeutics Inc ishlab chiqargan mahsulot

P/S koeffitsienti biznesning bozor qiymatini uning yillik daromadiga nisbatan aks ettiradi va bu qattiq monetar siyosat sharoitida aktivning investitsiya jozibadorligini baholash imkonini beradi. Narx/savdo nisbati dinamikasini tahlil qilish orqali investor kapitalizatsiyaning daromadga sezgirligini ko'rishi mumkin, bu esa tashqi ishlab chiqarishdan foydalanadigan Janux Therapeutics (JANX) ning aktivlari kam bo'lgan modeli uchun baholash jismoniy imkoniyatlarga egalik qilishdan ko'ra, R&D samaradorligiga bog'liqligini ta'kidlaydi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning daromadga nisbati ImmunityBio Corp IBRX|Immunocore Holdings - Kapitalizatsiyaning daromadga nisbati|P/S multiplikatori Arcus Corp RCUS|ZYME - Narxning daromadga nisbati|TNGX (tangotx.com) - Kapitalizatsiya va daromad nisbati|Iovance Corp (IOVA) - Narxning daromadga nisbati|Sotuvga nisbatan narx Immatics Corp (IMTX)|Kapitalizatsiyaning daromadga nisbati XNCR|CMPX - Narx/daromad multiplikatori|Kapitalizatsiyaning daromadga nisbati REPL (Replimune Corp)|Kapitalizatsiyaning sotish hajmiga nisbati LYEL|P/S multiplikatori IPHA (Innate Pharma)|Bozor kapitallashuvining daromadga nisbati PYXS|Compugen Limited - P/S multiplikatori|Sotuvga nisbatan narx IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Narxning daromadga nisbati|MiNK Therapeutics, Inc. - Bozor kapitallashuvining daromadga nisbati|HOWL (Werewolf) - P/S multiplikatori|P/S multiplikatori immixbio.com|Narxning daromadga nisbati ALX Oncology Holdings (ALXO)|CUE - Sotuvga nisbatan narx|PDS Biotechnology Corporation - Kapitalizatsiyaning daromadga nisbati|Sonnet BioTherapeutics (SONN) - Sotuvga nisbatan narx|MAIA - Narxning daromadga nisbati|LIMN: Narxning daromadga nisbati|LVTX: P/S multiplikatori|Sotuvga nisbatan narx NextCure, Inc. (NXTC)|LPTX (Leap Tx) - P/S multiplikatori|INTS (Intensity Therapeutics) - Kapitalizatsiyaning sotish hajmiga nisbati|Narxning daromadga nisbati Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati gritstonebio.com GRTS|Bozor kapitallashuvining daromadga nisbati KA|NEXI - Narxning daromadga nisbati|Turnstone Biologics Corp. - Kapitalizatsiyaning sotish hajmiga nisbati|VCNX: P/S multiplikatori|Kapitalizatsiya va daromad nisbati HARP